Thread by @MylesMcNulty

@avacta's AVA6000 approved by MHRA. Superb news. First dosing 'around mid-year'; first data to come within 3-4 months after that.

A summary thread on the significance of AVA6000 - and #AVCT's pre CISION platform as a whole - to both the oncology industry and to AVCT itself. 1/10

In very basic terms, #AVCT's pre CISION chemotherapies are essentially reformulated versions of existing, approved chemotherapies that have been used on cancer patients for many years - decades, even.

The pre CISION tech is simply an attempt to improve the safety profile... 2/10

...of the chemo.

Most therapeutics going through clinical trials look for an improvement of at least 20% over the existing industry-standard drug. A 50% increase in efficacy would usually be considered an astonishing result.

In pre-clinical mouse models for #AVCT's AVA6000 3/10

...18 times more pro-doxorubicin was found in the tumour than in the heart. Compare that to the 1:1 ratio of the standard doxorubicin.

What this means is that the pre CISION tech could be used to enable the giving of doses to patients that are multiple times more potent... 4/10

...than standard chemotherapy drugs - either in the form of greater number of cycles of chemo, or in the potency of the individual dose.

For example, in #AVCT's pre-clinical trials, pro-dox (AVA6000) doses were 6x more potent than the standard dox doses.

The results? The...5/10

...survival rate after 60 days for the standard-dox group was 0%; and 100% for the pro-dox group.

#AVCT isn't looking to improve chemotherapies by 25-30%, like most drugs in clinical trials.

Its pre CISION has the potential to improve the safety profile - and thus the... 6/10

...efficacy (via increased dosing) - by MULTIPLES. It is not an exaggeration to state that pre CISION could transform the chemo market - in fact, the overall oncology space. Survival rates could increase materially - as the mouse trials demonstrated. 7/10

avacta.com/wp-content/upl…

For #AVCT, it stands to reason that if the pro-dox trial is a success, then the pre CISION tech is also highly likely to work for other existing chemotherapies. @avacta has a pipeline of at least a dozen others in development.

AVCT holds the global exclusive licence over...8/10

...the pre CISION tech. It is also combining the tech with its second platform, Affimers - to create a third therapeutic platform, named TMAC.

TMAC will produce Affimer Drug Conjugates - a potentially more powerful class of oncology treatment than Antibody Drug Conjugates. 9/10

More on TMAC and AfDCs another time, but suffice to say that if they do work in man, #AVCT could become one of the most sought after oncology companies, globally.

First though, success for AVA6000 please!

Then hopefully @avacta's first TMAC drug to enter Phase I next year 10/10